Results 81 to 90 of about 238 (108)

Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential. [PDF]

Front Pharmacol
Sun M, Sun J, Sun W, Li X, Wang Z, Sun L, Wang Y.   +6 more
europepmc   +1 more source

Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring. [PDF]

Diabetes Ther, 2020
Kawaguchi Y, Sawa J, Kumeda Y.
europepmc   +1 more source

Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis. [PDF]

Front Pharmacol
Yang S, Hu Q, Liu K, Xiao B, Zhang B, Su N.   +5 more
europepmc   +1 more source

Sodium glucose cotransporter 2 inhibitor suppresses renal injury in rats with renal congestion. [PDF]

Hypertens Res
Endo A, Hirose T, Sato S, Ito H, Takahashi C, Ishikawa R, Kamada A, Oba-Yabana I, Kimura T, Takahashi K, Mori T.   +10 more
europepmc   +1 more source

Corrigendum: Novel approach to studying marine fauna: using long-life remote underwater video cameras to assess occurrence and behaviour of threatened and data-deficient elasmobranch species in southern Mozambique

Frontiers in Marine Science
Jule Buschmann, Jule Buschmann, Kim G. Roques, Jaime S. Davies, Jaime S. Davies, Awantha Dissanayake, Jennifer A. Keeping, Jennifer A. Keeping   +7 more
doaj   +1 more source

Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats. [PDF]

Cells
Asada S, Kaji K, Nishimura N, Koizumi A, Matsuda T, Tanaka M, Yorioka N, Sato S, Kitagawa K, Namisaki T, Akahane T, Yoshiji H.   +11 more
europepmc   +1 more source

The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review. [PDF]

J Clin Med
Stachteas P, Nasoufidou A, Karagiannidis E, Patoulias D, Karakasis P, Alexiou S, Samaras A, Zormpas G, Stavropoulos G, Tsalikakis D, Kassimis G, Papadopoulos C, Fragakis N.   +12 more
europepmc   +1 more source

Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction. [PDF]

Physiol Rep, 2018
Ito S, Hosaka T, Yano W, Itou T, Yasumura M, Shimizu Y, Kobayashi H, Nakagawa T, Inoue K, Tanabe S, Kondo T, Ishida H.   +11 more
europepmc   +1 more source

Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). [PDF]

Diabetes Obes Metab, 2018
Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K.   +4 more
europepmc   +1 more source

Influence of long term administration of tofogliflozin on chronic inflammation of visceral adipose tissue in mice with obesity induced by a high-fat diet. [PDF]

PLoS One, 2019
Shirakawa K, Yano W, Inoue K, Katsumata Y, Endo J, Sano M.   +5 more
europepmc   +1 more source